ETIDIOH - NEW

  {Excerpt} (...) Results NAb geometric mean titers against H1N1 WI/22, H3N2 BA/22, H3N2 CR/23, H3N2-K BA/25, and H3N2-K NY/25 were 200, 231, 119, 50, and 60 at baseline and increased to 582, 661, 356, 85, and 119 at peak immunogenicity, respectively (...), reflecting a significant 2.86- to 2.99-fold increase in NAb titers against the prior H1N1 and H3N2 strains but a lower 1.70- to 1.98-fold increase in NAb titers against the H3N2-K strains . Baseline antibody titers to the H3N2-K strains were 2.0- to 4.6-fold lower than to the prior H1N1 and H3N2 strains (P < .001), and peak antibody titers to the H3N2-K strains following vaccination were 3.0- to 7.8-fold lower than to the prior H1N1 and H3N2 strains (P < .001). (...) Source:  Link:  https://jamanetwork.com/journals/jama/fullarticle/2846268?guestAccessKey=10f1c0a1-4189-438d-9f71-a588fdd0db53&utm_medium=email&utm_source=postup_jn&utm_campaign=article_alert-jama&utm_content=olf-tfl_&utm_term=0309...

  Ann Intern Med SACKS HS In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKD. Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-26-00324. PubMed           Abstract available ANAND R, Glatt AE In healthy adults, a modified RNA vs. inactivated influenza vaccine reduced laboratory-confirmed influenza-like illness at >/=14 d. Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05681. PubMed           Abstract available Antiviral Res RUDRAMURTHY GR, Gudla CS, Harisha R, Selvam V, et al FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo. Antiviral Res. 2026 Mar 2:106382. doi: 10.1016/j.antiviral.2026.106382. PubMed           Abstract available Arch Virol DUTTA M, Sarmah N, Siddique AI, Borah...

  Abstract Wastewater monitoring enables non-invasive, population-scale tracking of community infections independent of healthcare-seeking behavior and clinical diagnosis. Metagenomic sequencing extends this capability by enabling broad, pathogen-agnostic detection, genomic characterization , and identification of novel or unexpected threats . Here, we present data from CASPER (the Coalition for Agnostic Sequencing of Pathogens from Environmental Reservoirs), a U.S.-based wastewater metagenomic sequencing network designed for deep, untargeted pathogen monitoring at national scale. This release includes 1,206 samples collected between December 2023 and December 2025 from 27 sites across nine states , covering 13 million people . Deep sequencing (~1 billion read pairs per sample) generated 1.2 trillion read pairs ( 347 terabases ), enabling detection of even rare taxa , with CASPER representing 66% of all untargeted wastewater sequencing data currently available on the NCBI Sequence ...

  Arch Virol KOBAYASHI D, Hiono T, Adachi R, Igarashi M, et al Length and density of alpha2-3 sialyllactose-containing chains on glycopolymers determine receptor binding of avian influenza viruses. Arch Virol. 2026;171:100. PubMed          PARK SH, Lee SH, Seo YR, Kim DJ, et al Evolution and spread of H8Nx avian influenza viruses from wild birds in East Asia, 2019-2024. Arch Virol. 2026;171:95. PubMed           Abstract available NAVEED A The bovine mammary gland as a crucible for zoonotic influenza virus emergence: Receptor-mediated adaptation of HPAI H5N1 clade 2.3.4.4b. Arch Virol. 2026;171:89. PubMed          Biochem Biophys Res Commun SINGH VA, Nehul S, Saha A, Singh V, et al Bioengineered chimeric VLPs targeting chikungunya virus and SARS-CoV-2 show high immunogenicity in mice. Biochem Biophys Res Commun. 2026;805:153346. PubMed        ...

  February 2026  WHO convenes technical consultations {1} in February and September each year to recommend viruses for inclusion in influenza vaccines {2} for the northern hemisphere (NH) and southern hemisphere (SH) influenza seasons, respectively.  This recommendation relates to the influenza vaccines for use in the NH 2026-2027 influenza season .  A recommendation will be made in September 2026 relating to vaccines that will be used for the SH 2027 influenza season.  WHO guidance for choosing between the NH and SH formulations for countries in tropical and subtropical regions is available on the WHO Global Influenza Programme website {3}.   National or regional authorities approve the composition and formulation of influenza vaccines used in each country.  National public health authorities are responsible for making recommendations regarding the use of the vaccine.  WHO has published recommendations on the prevention of influenza {4}....

  Abstract As part of its role in the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received 12,180 human influenza-positive samples during 2024 . Viruses were analysed for their antigenic, genetic, and antiviral susceptibility properties . Selected viruses were propagated in qualified cells or embryonated hens’ eggs for potential use in seasonal influenza virus vaccines. During 2024 , influenza A( H1N1 )pdm09 and A( H3N2 ) viruses predominated , accounting for 33% and 42%, respectively, of all viruses received, compared to 5% for influenza B/Victoria . Of note, one influenza A(H5N1) virus was also received in 2024 . The majority of A(H1N1)pdm09 (98%), A(H3N2) (88%) and influenza B (100%) viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2024...

  Antiviral Res WRONSKI S, Obernolte H, Schaudien D, Braun A, et al Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice. Antiviral Res. 2026;247:106362. PubMed           Abstract available HEDSKOG C, Rodriguez L, Hu Y, Li J, et al SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19. Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351. PubMed           Abstract available RODRIGUEZ L, Hu Y, Li J, Han D, et al SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19. Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339. PubMed           Abstract available Arch Virol LIM KS, Selvan ME, Ea CK...